New hope for tough prostate cancer: drug combo aims to delay progression

NCT ID NCT06844383

Recruiting now Disease control Sponsor: Prostate Cancer Clinical Trials Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene changes (HRR mutations) will be randomly assigned to one of two treatment groups. The main goal is to see how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Show contact details

Locations

Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact Email: •••••@•••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
University of Wisconsin Carbone Cancer Center-Madison
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.